Mineralys Therapeutics, Inc. (MLYS)
25.86
-0.73
(-2.75%)
USD |
NASDAQ |
Sep 25, 16:00
25.88
+0.02
(+0.08%)
After-Hours: 19:59
Mineralys Therapeutics EPS Diluted (Quarterly) : -2.845 for June 30, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -2.845 |
| March 31, 2026 | -0.4749 |
| December 31, 2025 | -0.4002 |
| September 30, 2025 | -0.5232 |
| June 30, 2025 | -0.6612 |
| March 31, 2025 | -0.794 |
| December 31, 2024 | -0.9797 |
| September 30, 2024 | -1.131 |
| June 30, 2024 | -0.831 |
| March 31, 2024 | -0.7017 |
| Date | Value |
|---|---|
| December 31, 2023 | -0.6083 |
| September 30, 2023 | -0.5537 |
| June 30, 2023 | -0.2972 |
| March 31, 2023 | -0.3086 |
| December 31, 2022 | -0.2221 |
| September 30, 2022 | -0.1635 |
| June 30, 2022 | -0.1586 |
| March 31, 2022 | -0.1853 |
| December 31, 2021 | -0.1205 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | -1.355 |
| Oncolytics Biotech, Inc. | -0.0788 |
| Sangamo Therapeutics, Inc. | -0.0796 |
| Sarepta Therapeutics, Inc. | -0.0464 |
| Anixa Biosciences, Inc. | -0.0762 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -241.07M |
| Total Expenses (Quarterly) | 241.07M |
| Enterprise Value | 1.721B |
| Earnings Yield | -16.41% |
| Normalized Earnings Yield | -16.41 |